immixbio.comCrawled Oct 29, 2026
Immix Biopharma invites patients with AL amyloidosis to participate in clinical trials for potential treatment.
Kfir-Erenfeld and colleagues publish feasibility data for academic BCMA-CART (HBI0101) in treating relapsed and refractory AL amyloidosis.
E Lebel, N Asherie, M Assayag, S Elias, S Grisariu, B Avni, S Kfir-Erenfeld, T Dubnikov-Sharon, R Alexander-Shani, N Bessig, A Shehadeh, A Ishtay, S Pimienta, V Vaistein, E Zimran, M Pick, Y C. Cohen, I Avivi Mazza, C Cohen, P Stepensky, and M E Gatt. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. 66th ASH Annual Meeting and Exposition, San Diego, CA, December 9, 2024.
A study explores the feasibility of an academic anti-BCMA CAR-T (HBI0101) for relapsed and refractory AL amyloidosis, presented at the International Myeloma Society Annual Meeting.
E. Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, C. Cohen, P. Stepensky, M.E. Gatt. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (NXC-201) for the Treatment of Relapsed and Refractory AL amyloidosis. International Society of Amyloidosis. May, 2024.
NXC-201 shows a 75% complete response rate in relapsed and refractory AL amyloidosis, with MRD negativity in bone marrow predicting future responses.
Immix Biopharma receives an $8 million grant from the California Institute for Regenerative Medicine to develop NXC-201 for relapsed/refractory AL amyloidosis.
Immix Biopharma completes dosing six patients in the safety run-in segment of NXC-201 trials, with positive early data announced in December 2024.
In a mouse study, IMX-110 achieves 75% survival compared to 0% for Trabectedin in soft tissue sarcoma.
Michael leads commercial operations at Immix Biopharma, bringing over 25 years of biopharmaceutical experience, including launching MODEYSO at Chimerix.